Contatti | Lavora con noi | Richiedi un preventivo| Download
Highligths in Colo-Rectal Cancer Management
23 novembre 2012
Sede del Corso:
Domus Nova Bethlem - Roma
RAZIONALE
Colorectal cancer is one of the most common causes of cancer-related death both in Europe
and in the . The incidence of new cases in is about 40,000/year. Approximately 25% of
patients with colorectal cancer present metastases at diagnosis and about 50% will develop
metastases at a later stage, with the liver being the most common site.
In the last decade substantial improvement of prognosis has been achieved and recent estimates show a trend toward a decreased mortality. This is due to a larger dissemination of screening, but also to advancement in medical therapy, both in the adjuvant and metastatic setting. Overall, the 5-year survival rate for patients with colorectal cancer is 60%, but in metastatic disease prognosis is still dismal ranging between less than 5 and 30%.
New agents and new strategies have permitted to increase survival also in metastatic
colorectal cancer. The use of all active drugs in combination of cytotoxic and biological
agents, the flexibility of treatment in relation to the clinical picture, the identification of
prognostic biomarkers as KRAS mutation status and the increasing diffusion of surgical
resection of metastases have contributed to quadruplicate life expectancy in metastatic
colorectal cancer. In fact, median survival has increased from 6 months to more than 24
months and conversion to surgery of previously unresectable metastatic disease plays an
important role in this result.
In this meeting all these topics will be discussed, including screening issues, biomarkers role,
combination therapy and conversion therapy. Participants will have the opportunity to hear
and to discuss the most recent advances in the management of colorectal cancer. Thanks to its
interactive structure, at the end of the meeting they will have developed up-to-date knowledge
and ability in the main areas of research in colorectal cancer.
PROGRAMMA
8.30
Registration
9.00 - 11.00
Introduction
Carlo Barone, Rome
1 Life style and prevention of colon cancer, Clara Natoli, Chieti
B SERIE DI RELAZIONI SU TEMA PREORDINATO
2 Tissue and circulating biomarkers, Alberdo Bardelli, Turin
B SERIE DI RELAZIONI SU TEMA PREORDINATO
3 Morphology and enhancement criteria in radiologic imaging, Dottor Macis, Rome
B SERIE DI RELAZIONI SU TEMA PREORDINATO
11.00-11.30
Coffee Break
11.30-13.00
4 Critical methodologic issues in recent randomized trials, Dottor Bruzzi, Genoa
B SERIE DI RELAZIONI SU TEMA PREORDINATO
5 Adjuvant therapy of colorectal cancer, Corrado Boni, Reggio Emilia
B SERIE DI RELAZIONI SU TEMA PREORDINATO
6 Treatment of metastatic disease, Mario Scartozzi, Ancona
B SERIE DI RELAZIONI SU TEMA PREORDINATO
13.00 - 14.00
Lunch
14.00-16.00
7 .Surgical approach to metastatic disease, Felice Giuliante, Rome
B SERIE DI RELAZIONI SU TEMA PREORDINATO
8 Primary therapy of liver metastases: is it always an incremental value? Carmelo Pozzo, Rome
B SERIE DI RELAZIONI SU TEMA PREORDINATO
9 Management of rectal cancer, Carmine Pinto, Bologna
B SERIE DI RELAZIONI SU TEMA PREORDINATO
10 Is there a clinical approach to colorectal cancer? Carlo Garufi, Rome
16.00- 16.30
Discussion & Conclusion
Vedi la Brochure